E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with recurrent NSCLC. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029519 |
E.1.2 | Term | Non-small cell lung cancer stage III |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To evaluate the effect of the combination of erlotinib and MK-0646 on PFS in patients with recurrent NSCLC. HYPOTHESIS: Administration of erlotinib in combination with MK-0646 in patients with recurrent NSCLC results in improvement in PFS compared to patients treated with erlotinib alone. |
|
E.2.2 | Secondary objectives of the trial |
Radiological: To quantify response rate (RR) by response criteria in solid tumors (RECIST) criteria. 2. Clinical: To determine overall survival (OS). HYPOTHESIS: Administration of erlotinib in combination with MK-0646 in patients with recurrent NSCLC improves RR and OS compared to patients treated with erlotinib alone. 2.1.3 Tertiary 1. To assess the human-anti-humanized-antibody (HAHA) response to MK-0646. 2.1.4 Exploratory Objective 1. To assess the correlation of IGF-1R expression with clinical response and safety and evaluate biomarker expression in the IGFR and EGFR signaling pathway in archival paraffin-embedded tumor specimens by IHC and mutation analysis. 2. Phase I: To correlate pharmacokinetic parameter values for erlotinib and MK-0646 therapy with safety. Phase II: To correlate MK-0646 trough levels with clinical response. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must meet all of the following criteria to participate in this study: 1. Patient has histologically or cytologically documented, unresectable, locally advanced or metastatic Stage IIIB/IV NSCLC that has relapsed after chemotherapy/chemoradiotherapy. 2. Patient has a pre-study, diagnostic formalin fixed paraffin-embedded tumor tissue sample available for correlative studies. Sample is OPTIONAL in the Phase I portion of the study. Sample is REQUIRED in the Phase II portion of the study. 3. Patient has measurable disease based on RECIST criteria. 4. Patient has had at least one systemic chemotherapy regimen for recurrent or metastatic disease. 5. Patient is male or female, and 18 years of age on the day of signing informed consent. 6. Patient has a performance status 0-2 on the ECOG Performance Scale. 7. Patient must have adequate organ function as indicated by the following laboratory values. Female patient of childbearing potential has a negative serum/urine pregnancy test at baseline, 9. Male and female patients, as well as their partners, must agree to use adequate contraception during therapy with MK-0646 alone or in combination with erlotinib. Note that simultaneous use of two reliable forms of contraception is recommended for the entire study period and ending 28±2 days after the last dose of study drug. |
|
E.4 | Principal exclusion criteria |
A patient meeting any of the following criteria is not eligible to participate in this study: 1. Patient who has had chemotherapy or therapeutic radiotherapy within 2 weeks, or biological therapy such as bevacizumab (Avastin ) within 4 weeks, prior to entering the study or who has not recovered from adverse events due to agents administered more than 4 weeks earlier to at least grade 1 or baseline. Patient who has received prior EGFR TKI inhibitor/anti-EGFR mAb therapy or prior IGF-1R - TKI inhibitor/anti-IGF-1R mAb therapy. 3. Patient who has received more than 2 prior systemic chemotherapy regimens for recurrent or metastatic disease. 4. Patient who has not completed radiotherapy with complete resolution of toxicities at least 2 weeks prior to beginning this study. 5. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days (or 5 half-lives of the investigational compound) of initial dosing with study drug. 6. Patients with active central nervous system (CNS) metastases and/or carcinomatous meningitis are excluded. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 3 months prior to entry as defined as: (1) no evidence of new or enlarging CNS metastasis (2) off steroids or on a stable dose of steroids. 7. Patient with a primary central nervous system tumor. 8. Patient has known hypersensitivity to the components of study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this protocol is the difference in PFS between treatment groups; |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |